Longitudinal Lipid Screening and Use of Lipid-Lowering Medications in Pediatric Type 1 Diabetes - 12/08/11
, R. Paul Wadwa, MD, Kim McFann, PhD, Kristen Nadeau, MD, Matthew R. Williams, BS, Robert H. Eckel, MD, Georgeanna J. Klingensmith, MD
Reprint requests: Dr David M. Maahs, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 1775 Ursula St, PO Box 6511, Mail Stop A140, Aurora, CO 80045.Résumé |
Objective |
Because cardiovascular disease (CVD) is the leading cause of death in patients with type 1 diabetes (T1D) and dyslipidemia is an important CVD risk factor, we investigated dyslipidemia and its treatment in children with T1D.
Study design |
Subjects had T1D (n = 360), repeated lipid measurements (n = 1095; mean, 3.04 ± 0.94; range, 2 to 11), and were seen between 1994 and 2004. Total cholesterol (TC), high-density lipoprotein cholesterol (HDL), and non-HDL cholesterol (non-HDL) were categorized on the basis of published guidelines. Age, diabetes duration, sex, body mass index, HbA1c, and lipid-lowering medication use were recorded. Predictors of TC, HDL, and non-HDL were determined.
Results |
Sustained abnormalities existed for TC ≥200 mg/dL (16.9%); HDL <35 mg/dL (3.3%); and non-HDL ≥130 mg/dL (27.8%), ≥160 mg/dL (10.6%), and ≥190 mg/dL (3.3%). Lipid-lowering medications were started on 23 patients. In mixed model longitudinal data analyses, HbA1c was significantly related to TC and non-HDL. Body mass index z-score was inversely related to HDL.
Conclusions |
In this retrospective, longitudinal study of pediatric patients with T1D with repeated lipid measurements, sustained abnormal levels for TC, HDL, and non-HDL were present. Prospective longitudinal data for dyslipidemia in youth with T1D are needed.
Le texte complet de cet article est disponible en PDF.Abbreviations : ADA, BMI, CVD, HDL, TC, T1D
Plan
| Support for this study was provided by National Institutes of Health grants T32 DK063687-03 (Dr Maahs), K23RR020038-02 (Dr Nadeau), and K12 DK063722-03 (Dr Wadwa), and Diabetes Education Research Center Grant P30 DK57516. |
Vol 150 - N° 2
P. 146 - février 2007 Retour au numéro
Article précédent
- Diagnosis and Localization of Focal Congenital Hyperinsulinism by 18F-Fluorodopa PET Scan
- Olga T. Hardy, Miguel Hernandez-Pampaloni, Janet R. Saffer, Mariko Suchi, Eduardo Ruchelli, Hongming Zhuang, Arupa Ganguly, Richard Freifelder, N. Scott Adzick, Abass Alavi, Charles A. Stanley
- Altered Basal Cortisol Levels at 3, 6, 8 and 18 Months in Infants Born at Extremely Low Gestational Age
- Ruth E. Grunau, David W. Haley, Michael F. Whitfield, Joanne Weinberg, Wayne Yu, Paul Thiessen
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?